Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 


Trans-Tasman collaboration leads to new rotavirus vaccine

Trans-Tasman collaboration leads to new rotavirus vaccine


Thursday 4 September 2014

A new rotavirus vaccine that has the potential to save over half a million lives worldwide each year has reached a pivotal milestone after clinical trials results found the vaccine provided a strong immune response in over 90 per cent of babies that received a course of the vaccine.

Rotavirus is the most common cause of severe diarrhoea among infants and young children and results in the death of over half a million children under five years of age worldwide each year, mainly in developing countries.

The clinical trial, which was done in collaboration between the University of Otago and the Murdoch Childrens Research Institute at the University of Melbourne, involved 95 babies at Dunedin Hospital receiving a course of three doses of the vaccine, with the first dose given within the first days of birth.

The breakthrough results will be presented at the 11th International Rotavirus Symposium currently underway in New Delhi, India.

Lead researcher, Professor Julie Bines of Murdoch Childrens, the University of Melbourne and The Royal Children’s Hospital said the results provide confidence that this vaccine will be very effective in preventing severe rotavirus gastroenteritis in very young babies.

“These results are a major step forward for the development of the vaccine as it is the first time a rotavirus vaccine has been given to newborns. Not only have we shown that this novel vaccine is well tolerated in newborns but it produces a strong immune response in a newborn, suggestive of promoting early protection from severe gastroenteritis,” she says.

“The advantage of this vaccine over the currently available vaccines is the birth dose which is the earliest opportunity to provide protection to babies from severe rotavirus gastroenteritis. This world-first approach has enormous potential to reduce disease and dying in the most vulnerable children around the world.”

The ‘RV3’ Rotavirus Vaccine candidate has been developed from a unique strain of rotavirus that was found naturally in healthy asymptomatic newborn babies, who were then protected from severe rotavirus diarrhea in the first two years of life.

University of Otago Senior Clinical Lecturer in Women and Children’s Health Dr Pam Jackson says the clinical trial in Dunedin went very well, and she thanks families for their participation, and also the Health Research Council (HRC) of New Zealand, which funded the study.

“Without their willingness to help this would have been difficult to assess, and we are delighted that this vaccine has been shown to be an effective way to prevent this disease.”

Newborn babies and infants in Dunedin were given three doses of the oral vaccine, called RV3-BB, or a placebo to ascertain the level of immunity to rotavirus generated by the vaccine. The vaccine is derived from a harmless strain of rotavirus found in newborn babies. In New Zealand, rotavirus is responsible for 1500 hospital admissions of children under five years of age each year.

Although babies in Australia have had the benefit of rotavirus vaccines the new vaccine has a number of advantages, such as the ability to administer earlier and prevent disease in very young babies that are currently not protected.

The research and development of the ‘RV3’ vaccine is being led and conducted by academic institutions rather than the pharmaceutical industry with the intention to partner with developing country manufacturers so that the vaccine will ultimately be affordable for developing countries, where they are needed most.

The vaccine is the culmination of over four decades of research in Australia by the Murdoch Childrens Research Institute, The Royal Children's Hospital Melbourne and the University of Melbourne, following the discovery of rotavirus by a team of staff led by Professor Ruth Bishop in 1973.

Clinical trials are also underway in Indonesia. It is hoped the vaccine will be available for widespread use in 2016.
ends

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Housing: Affordability Drops 14%, Driven By Auckland Prices

Housing affordability across New Zealand fell 14 percent in the year ending November 2014, with Auckland’s lack of affordability set to reach levels it hit during the height of the global financial crisis, according to the latest Massey University Home Affordability Report More>>

ALSO:

The Dry: Fonterra Drops Forecast Milk Volumes By 3.3 Percent

Fonterra Cooperative Group, the worlds largest dairy exporter, reduced its milk volume forecast for the 2014-2015 season by 3.3 per cent due to the impact of dry weather on production in recent weeks. More>>

ALSO:

Strike: Lyttelton Port Workers Vote To Escalate Dispute

Members of the Rail and Maritime Transport Union (RMTU) at Lyttelton Port today voted to escalate their industrial action. Around 200 RMTU members have been operating an overtime ban since 17 December and today they endorsed a series of full withdrawals of labour at the port. More>>

ALSO:

Scoop Business: NZ Dollar Falls To 3-Year Low As Investors Favour Greenback

The New Zealand dollar fell to its lowest in more than three years as investors sold euro and bought US dollars, weakening other currencies against the greenback. More>>

ALSO:

Scoop Business: NZ Govt Operating Deficit Smaller Than Expected

The New Zealand’s government’s operating deficit was smaller than expected in the first five months of the financial year as a clampdown on expenditure managed to offset a shortfall in the tax-take from last month’s forecast. More>>

ALSO:

0.8 Percent Annually:
NZ Inflation Falls Below RBNZ's Target

New Zealand's annual pace of inflation slowed to below the Reserve Bank's target band in the final three months of the year, giving governor Graeme Wheeler more room to keep the benchmark interest rate lower for longer.More>>

ALSO:

Get More From Scoop

 
 
Standards New Zealand

Standards New Zealand
 
 
 
 
 
 
 
 
Sci-Tech
Search Scoop  
 
 
Powered by Vodafone
NZ independent news